Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Management
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • Scientific Advisory Committee
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
      • Sponsor/ Advisor
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: 2017

LA TRIBUNE – Cancer : Onxeo vise une nouvelle stratégie thérapeutique pour “contenir l’évolution de la maladie”

02/07/201710/08/2019

Read the article in  La Tribune (in French)  

CLINICAL LEADER – The Science Of M&A: Making The Most Of Your Financial Resources

02/16/201710/08/2019

  Read the article on clinicalleader.com  

Onxeo launches a capital increase by means of an accelerated book-build offering

06/19/201710/03/2019

Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]

Onxeo successfully raises €15 Million with US and European investors

06/20/201710/03/2019

Offering upsized in response to investor demand   Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. […]

Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration

07/05/201710/03/2019

Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 […]

Onxeo Reports First-Half 2017 Results and Business Update

07/28/201710/03/2019

Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core […]

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

07/31/201710/03/2019

Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – […]

Onxeo Grants Exclusive Worldwide License of Validive® developed for the treatment of oral severe mucositis to Monopar Therapeutics

09/13/201710/03/2019

Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future sales Monopar Therapeutics will drive […]

Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag®

09/18/201710/03/2019

Paris (France), September 18, 2017 – 8:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat

09/28/201710/03/2019

Results demonstrate a very strong synergistic effect between AsiDNA™,  first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) […]

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

10/02/201710/03/2019

2 OCT., 2017 PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its […]

Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm

10/17/201710/03/2019

Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma

09/11/201710/03/2019

Paris (France), September 11, 2017 – 8:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), […]

Onxeo to attend Key Investor and Partnering Conferences in H1 2018

01/03/201809/24/2019

Paris (France), January 3, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

01/24/201709/11/2019

Milestone completion in line with expected preliminary outcomes mid-2017  Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – […]

Onxeo receives the EnterNext Tech 40 Label

04/20/201709/11/2019

Onxeo is admitted to the “Tech 40” index, which incorporates 40 outstanding small and midcap Tech companies listed on the […]

Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting

11/28/201709/10/2019

Professor Tomas Lindahl, DNA Repair Pioneer and 2015 Nobel Prize laureate, will serve as Chair of the Scientific Advisory Board […]

Combined General Meeting on April 26, 2017

04/05/201709/06/2019

Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Annual General Meeting of April 26, 2017

04/26/201709/06/2019

All ordinary resolutions approved Two new independent directors appointed Renewal of the terms of office of Mrs Judith Greciet, CEO, […]

Publication of 2016 Registration Document

04/25/201709/04/2019

Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]

Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

01/31/201709/04/2019

The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), […]

Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

02/08/201709/04/2019

Paris (France), February 8, 2017 – 8.30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology […]

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

02/13/201709/04/2019

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 […]

Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development

03/01/201709/04/2019

Françoise Bono, PhD, Named Chief Scientific Officer to Lead Preclinical Activities Olivier de Beaumont, MD, MBA, Appointed Chief Medical Officer […]

Full-year 2016 Results and Outlook for 2017

03/07/201709/04/2019

Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, […]

Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting

03/21/201709/04/2019

Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext […]

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

04/24/201709/04/2019

Paris, April 24, 2017 – 18 :30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) […]

Onxeo: Q1 2017 financial information and business update

04/26/201709/04/2019

    Revenues up 55% to €1.2 million     Cash position of €21.7 million at March 31, 2017     All strategic […]

Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma

05/10/201709/04/2019

USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims […]

Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC

05/23/201709/04/2019

Paris (France), May 23, 2017 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology […]

Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information

10/26/201709/04/2019

Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotides Development of lead product AsiDNA™ […]

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

185 Alewife Brook Parkway
Suite 210, Cambridge, MA 02138
(617) 648-8674

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2023 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress